Cycloserine did not increase depression incidence or severity at standard dosing for multidrug-resistant tuberculosis

ARTICLE: Cycloserine did not increase depression incidence or severity at standard dosing for multidrug-resistant tuberculosis

AUTHORS: Jeffrey A Tornheim, Zarir F Udwadia, Prerna R Arora, Ishita Gajjar, Nikhil Gupte, Samridhi Sharma, Megha Karane, Namrata Sawant, Nisha Kharat, Alexander J Blum, Shri Vijay Bala Yogendra Shivakumar, Jai B Mullerpattan, Lancelot M Pinto, Tester F Ashavaid, Amita Gupta, Camilla Rodrigues

JOURNAL: Eur Respir J. 2022 Mar 24;59(3):2102511. doi: 10.1183/13993003.02511-2021. Print 2022 Mar.

Abstract

In a longitudinal cohort of MDR-TB patients receiving individualised, DST-based treatment, neither the inclusion of cycloserine in a multidrug regimen nor the dose used (up to 750 mg daily) significantly increased incidence of depression during treatment.

For the full article, click here.

For a link to the abstract, click here.